Sglt 2 denied as non-formulary by Aetna?

Aetna's specific coverage criteria for sglt2 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies an SGLT2 Inhibitor as Non-Formulary

Aetna's formulary designates covered drugs by tier. A non-formulary denial means the specific SGLT2 inhibitor prescribed is either not listed on the plan's formulary at all, or is placed on a tier requiring a formulary exception before the plan will cover it. This is one of the most common prescription-drug denial categories and is frequently resolved through a formulary exception process.

Formulary exception requests succeed most often when the prescriber documents that a formulary alternative is clinically unsuitable for the specific patient — due to a past inadequate response, tolerability issue, or a difference in FDA-approved indications relevant to the patient's condition.

## Federal Appeal Framework

• Formulary exception + internal appeal (run simultaneously) — Aetna has a parallel formulary exception process; filing both preserves your rights and maximizes speed. ERISA plans must decide urgent/expedited appeals within 72 hours and standard appeals within 30 days.
• External review (ACA §2719 / ERISA §503) — if the internal appeal and formulary exception are both denied, independent external review is available. The external-review window is generally within approximately four months of the original denial. Expedited review is available for urgent situations.
• State-level formulary exception laws — many states require insurers to grant exceptions when a non-formulary drug is medically necessary and no formulary alternative is clinically appropriate. Verify whether your state's law applies to your plan type.

## Documentation to Gather

• Aetna's current formulary and non-formulary exception criteria — identify the formulary SGLT2 inhibitor(s) Aetna considers alternatives, and the specific exception criteria that apply.
• FDA-approved prescribing labels — compare the label for the prescribed agent and the formulary alternative. Note any differences in approved indications, particularly for cardiovascular, heart failure, or renal indications.
• Prescriber letter of medical necessity — the prescriber should explain why the prescribed SGLT2 inhibitor is necessary for this patient, why the formulary alternative is not clinically equivalent for this patient's specific condition(s), and cite the relevant guideline organization's guidance by name.
• Prior-treatment history with the formulary alternative — if the patient has already tried the formulary drug and experienced inadequate response or intolerance, document this with dates and clinical detail.
• Diagnosis and comorbidity documentation — if the prescribed agent carries a distinct FDA-approved indication relevant to a comorbidity the formulary alternative lacks, document that comorbidity thoroughly.

## Criteria-Mapping Structure

| Non-Formulary Exception Criterion | Supporting Evidence | |---|---| | Formulary alternative tried and failed | [Drug name, dates, outcome] | | Formulary alternative contraindicated | [Clinical reason, prescriber note] | | Prescribed drug has unique indication for this patient | [Label indication + patient diagnosis] | | Guideline support for prescribed agent | [Guideline organization name + recommendation] |

## Key Argument

Non-formulary denials are administrative, not clinical. The exception process exists precisely for patients whose clinical profile makes the formulary alternative inappropriate. A well-documented formulary exception request — with a clear explanation of why alternatives are not suitable for this specific patient — resolves the majority of these denials without requiring full external review.